Edwards Granted CE Mark For First Transcatheter Tricuspid Therapy

IRVINE, Calif., April 30, 2018 /PRNewswire/ -- Edwards Lifesciences Corporation (NYSE: EW), the global leader in patient-focused innovations for structural heart disease and critical care monitoring, today announced that it has received CE Mark for the Edwards Cardioband Tricuspid Valve Reconstruction System for the treatment of tricuspid regurgitation. The Cardioband Tricuspid System is the first commercially available transcatheter therapy for the treatment of tricuspid heart valve...This story is related to the following:Medical Devices
Source: Industrial Newsroom - Health, Medical and Dental Supplies - Category: Medical Devices Source Type: news